170 related articles for article (PubMed ID: 7319736)
21. The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer.
Niell HB; Neely CL; Palmieri GM; McDonald MW
Cancer; 1983 Oct; 52(8):1442-7. PubMed ID: 6616407
[TBL] [Abstract][Full Text] [Related]
22. [Urinary polyamines and hydroxyproline in patients with breast cancer].
Solov'ev IE; Iurzhenko NN
Vrach Delo; 1986 Jun; (6):80-4. PubMed ID: 3750970
[No Abstract] [Full Text] [Related]
23. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
24. Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
Dady PJ; Coombes RC; Smith IE; Parsons CA; Ford HT; Gazet JC; Henk JM; Nash AG; Powles TJ
Eur J Cancer (1965); 1980; Suppl 1():131-5. PubMed ID: 6459234
[No Abstract] [Full Text] [Related]
25. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
26. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
27. Early morning hydroxyproline excretion in patients with breast cancer.
Powles TJ; Rosset G; Leese CL; Bondy PK
Cancer; 1976 Dec; 38(6):2564-6. PubMed ID: 1000483
[TBL] [Abstract][Full Text] [Related]
28. [Hydroxyprolinuria and bone metastases of breast cancer].
Cruciani G; Bardella D; Fiorentini GM; Marangolo M; Tavolazzi L
Tumori; 1980 Apr; 66(2):205-13. PubMed ID: 7445102
[TBL] [Abstract][Full Text] [Related]
29. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.
Clar H; Langsenlehner U; Krippl P; Renner W; Leithner A; Gruber G; Hofmann G; Yazdani-Biuki B; Langsenlehner T; Windhager R
Breast Cancer Res Treat; 2008 Oct; 111(3):449-52. PubMed ID: 17978878
[TBL] [Abstract][Full Text] [Related]
30. [Excretion of urinary hydroxyproline in urinary tract diseases].
Guarino A; Comar OB; Taccone W; Cicalese V
Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
[TBL] [Abstract][Full Text] [Related]
32. Urinary hydroxyproline excretion and survival in cancer of the breast.
Cuschieri A
Clin Oncol; 1975 Jun; 1(2):127-30. PubMed ID: 1183101
[No Abstract] [Full Text] [Related]
33. Urinary hydroxyproline excretion in carcinoma of the breast.
Cuschieri A; Felgate RA
Br J Exp Pathol; 1972 Jun; 53(3):237-41. PubMed ID: 5055709
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic value of whole-body MRI and bone scintigraphy in the detection of osseous metastases in patients with breast cancer--A Prospective Double-Blinded Study at two Hospital Centers].
Ohlmann-Knafo S; Kirschbaum M; Fenzl G; Pickuth D
Rofo; 2009 Mar; 181(3):255-63. PubMed ID: 19229791
[TBL] [Abstract][Full Text] [Related]
35. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
36. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
37. Proceedings: Urinary hydorxyproline excretion in the monitoring of carcinoma of the breast.
Lester E
Br J Radiol; 1976 Mar; 49(579):290. PubMed ID: 1276611
[No Abstract] [Full Text] [Related]
38. Influence of estradiol and estriol on urinary excretion of hydroxyproline in man.
Katz FH; Kappas A
J Lab Clin Med; 1968 Jan; 71(1):65-74. PubMed ID: 5635010
[No Abstract] [Full Text] [Related]
39. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
40. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
